Role of plasminogen activator inhibitor-1 in senescence and aging

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 6, 2014, Pages 645-651

  Eren, Mesut ^a   Boe, Amanda E ^a   Klyachko, Ekaterina A ^a   Vaughan, Douglas E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

aging; PAI 1; senescence

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 3;

AGING; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL COMMUNICATION; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; INFLAMMATION; ISCHEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SENESCENCE; VEIN OCCLUSION; VEIN THROMBOSIS; ANIMAL; DISEASE MODEL; METABOLISM; MOUSE;

AGING; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 84928549363     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1387883     Document Type: Article

References (68)

1. Rodier F., Campisi J. Four faces of cellular senescence. J Cell Biol: 2011; 192 4 547 556
2. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol: 2007; 8 9 729 740
3. Lijnen H. R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost: 2001; 86 1 324 333
4. Lijnen H. R., Van Hoef B., Lupu F., Moons L., Carmeliet P., Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol: 1998; 18 7 1035 1045
5. Abbate R., Prisco D., Rostagno C., Boddi M., Gensini G. F. Age-related changes in the hemostatic system. Int J Clin Lab Res: 1993; 23 1 1 3
6. Gleerup G., Winther K. The effect of ageing on platelet function and fibrinolytic activity. Angiology: 1995; 46 8 715 718
7. Meade T. W., Chakrabarti R., Haines A. P., North W. R., Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. BMJ: 1979; 1 6157 153 156
8. Aillaud M. F., Pignol F., Alessi M. C., et al. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age. Thromb Haemost: 1986; 55 3 330 332
9. Aznar J., Estellés A. Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases. Haemostasis: 1994; 24 4 243 251
10. Smith L. H., Dixon J. D., Stringham J. R., et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood: 2006; 107 1 132 134
11. Meltzer M. E., Lisman T., de Groot P. G., et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood: 2010; 116 1 113 121
12. Thögersen A. M., Jansson J. H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation: 1998; 98 21 2241 2247
13. Hamsten A., de Faire U., Walldius G., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet: 1987; 2 8549 3 9
14. Kochtebane N., Alzahrani A. M., Bartegi A. Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves. Biochem Res Int: 2014; 2014 658643
15. Juhan-Vague I., Alessi M. C. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost: 1997; 78 1 656 660
16. Alessi M. C., Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol: 2006; 26 10 2200 2207
17. Sawdey M., Podor T. J., Loskutoff D. J. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem: 1989; 264 18 10396 10401
18. Estellés A., Dalmau J., Falcó C., et al. Plasma PAI-1 levels in obese children-effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost: 2001; 86 2 647 652
19. Lindeman J. H., Pijl H., Toet K., et al. Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int J Obes (Lond): 2007; 31 11 1671 1679
20. Barbato A., Iacone R., Tarantino G., et al. Olivetti Heart Study Research Group Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. Intern Emerg Med: 2009; 4 4 315 323
21. Festa A., D'Agostino R. Jr, Tracy R. P., Haffner S. M. Insulin Resistance Atherosclerosis Study Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes: 2002; 51 4 1131 1137
22. Kanaya A. M., Wassel Fyr C., Vittinghoff E., et al. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med: 2006; 166 3 350 356
23. Schneiderman J., Sawdey M. S., Keeton M. R., et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A: 1992; 89 15 6998 7002
24. Raghunath P. N., Tomaszewski J. E., Brady S. T., Caron R. J., Okada S. S., Barnathan E. S. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol: 1995; 15 9 1432 1443
25. Lupu F., Heim D. A., Bachmann F., Hurni M., Kakkar V. V., Kruithof E. K. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol: 1995; 15 9 1444 1455
26. Robbie L. A., Booth N. A., Brown A. J., Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol: 1996; 16 4 539 545
27. Sobel B. E., Woodcock-Mitchell J., Schneider D. J., Holt R. E., Marutsuka K., Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation: 1998; 97 22 2213 2221
28. Pandolfi A., Cetrullo D., Polishuck R., et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol: 2001; 21 8 1378 1382
29. Hou B., Eren M., Painter C. A., et al. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem: 2004; 279 18 18127 18136
30. Quax P. H., van den Hoogen C. M., Verheijen J. H., et al. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem: 1990; 265 26 15560 15563
31. Arndt P. G., Young S. K., Worthen G. S. Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway. J Immunol: 2005; 175 6 4049 4059
32. Yamamoto K., Shimokawa T., Yi H., et al. Aging accelerates endotoxin-induced thrombosis: increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. Am J Pathol: 2002; 161 5 1805 1814
33. Sobel B. E., Lee Y. H., Pratley R. E., Schneider D. J. Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age. Life Sci: 2006; 79 17 1600 1605
34. Balaoing L. R., Post A. D., Liu H., Minn K. T., Grande-Allen K. J. Age-related changes in aortic valve hemostatic protein regulation. Arterioscler Thromb Vasc Biol: 2014; 34 1 72 80
35. Yamamoto K., Takeshita K., Shimokawa T., et al. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A: 2002; 99 2 890 895
36. Emeis J. J., Van den Hoogen C. M. Pharmacological modulation of the endotoxin-induced increase in plasminogen activator inhibitor activity in rats. Blood Coagul Fibrinolysis: 1992; 3 5 575 581
37. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature: 1997; 390 6655 45 51
38. Takeshita K., Yamamoto K., Ito M., et al. Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, Klotho mouse. Semin Thromb Hemost: 2002; 28 6 545 554
39. Baker D. J., Perez-Terzic C., Jin F., et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol: 2008; 10 7 825 836
40. Baker D. J., Wijshake T., Tchkonia T., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature: 2011; 479 7372 232 236
41. Burt V. L., Cutler J. A., Higgins M., et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension: 1995; 26 1 60 69
42. Boe A. E., Eren M., Murphy S. B., et al. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation: 2013; 128 21 2318 2324
43. Kaikita K., Fogo A. B., Ma L., Schoenhard J. A., Brown N. J., Vaughan D. E. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation: 2001; 104 7 839 844
44. Kaikita K., Schoenhard J. A., Painter C. A., et al. Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition. J Mol Cell Cardiol: 2002; 34 6 617 627
45. Eren M., Gleaves L. A., Atkinson J. B., King L. E., Declerck P. J., Vaughan D. E. Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. J Thromb Haemost: 2007; 5 7 1500 1508
46. Eren M., Painter C. A., Atkinson J. B., Declerck P. J., Vaughan D. E. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation: 2002; 106 4 491 496
47. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell: 2005; 120 4 513 522
48. Minamino T., Miyauchi H., Yoshida T., Ishida Y., Yoshida H., Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation: 2002; 105 13 1541 1544
49. Chen J. H., Hales C. N., Ozanne S. E. DNA damage, cellular senescence and organismal ageing: causal or correlative? Nucleic Acids Res: 2007; 35 22 7417 7428
50. Cardus A., Uryga A. K., Walters G., Erusalimsky J. D. SIRT6 protects human endothelial cells from DNA damage, telomere dysfunction, and senescence. Cardiovasc Res: 2013; 97 3 571 579
51. Comi P., Chiaramonte R., Maier J. A. Senescence-dependent regulation of type 1 plasminogen activator inhibitor in human vascular endothelial cells. Exp Cell Res: 1995; 219 1 304 308
52. Martens J. W., Sieuwerts A. M., Bolt-deVries J., et al. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thromb Haemost: 2003; 89 2 393 404
53. Mu X. C., Higgins P. J. Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent IMR-90 human diploid fibroblasts. J Cell Physiol: 1995; 165 3 647 657
54. Serrano M., Lin A. W., McCurrach M. E., Beach D., Lowe S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell: 1997; 88 5 593 602
55. West M. D., Shay J. W., Wright W. E., Linskens M. H. Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. Exp Gerontol: 1996; 31 1-2 175 193
56. Collado M., Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer: 2006; 6 6 472 476
57. Goldstein S., Moerman E. J., Fujii S., Sobel B. E. Overexpression of plasminogen activator inhibitor type-1 in senescent fibroblasts from normal subjects and those with Werner syndrome. J Cell Physiol: 1994; 161 3 571 579
58. Kortlever R. M., Bernards R. Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle: 2006; 5 23 2697 2703
59. Kortlever R. M., Higgins P. J., Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol: 2006; 8 8 877 884
60. Elzi D. J., Lai Y., Song M., Hakala K., Weintraub S. T., Shiio Y. Plasminogen activator inhibitor 1-insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. Proc Natl Acad Sci U S A: 2012; 109 30 12052 12057
61. Kortlever R. M., Brummelkamp T. R., van Meeteren L. A., Moolenaar W. H., Bernards R. Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling. Mol Cancer Res: 2008; 6 9 1452 1460
62. Lara P. C., Lloret M., Valenciano A., et al. Plasminogen activator inhibitor-1 (PAI-1) expression in relation to hypoxia and oncoproteins in clinical cervical tumors. Strahlenther Onkol: 2012; 188 12 1139 1145
63. Offersen B. V., Alsner J., Ege Olsen K., et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol: 2008; 47 4 618 632
64. Testa R., Bonfigli A. R., Salvioli S., et al. The Pro/Pro genotype of the p53 codon 72 polymorphism modulates PAI-1 plasma levels in ageing. Mech Ageing Dev: 2009; 130 8 497 500
65. Eren M., Boe A. E., Murphy S. B., et al. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proc Natl Acad Sci U S A: 2014; 111 19 7090 7095
66. Nelson G., Wordsworth J., Wang C., et al. A senescent cell bystander effect: senescence-induced senescence. Aging Cell: 2012; 11 2 345 349
67. Heberlein K. R., Han J., Straub A. C., et al. A novel mRNA binding protein complex promotes localized plasminogen activator inhibitor-1 accumulation at the myoendothelial junction. Arterioscler Thromb Vasc Biol: 2012; 32 5 1271 1279
68. Heberlein K. R., Straub A. C., Best A. K., et al. Plasminogen activator inhibitor-1 regulates myoendothelial junction formation. Circ Res: 2010; 106 6 1092 1102